88 related articles for article (PubMed ID: 24309323)
1. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
2. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
Kang EY; Weir A; Meagher NS; Farrington K; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Bolithon A; Popovic G; Leung B; Tang K; Lambie N; Millstein J; Alsop J; Anglesio MS; Ataseven B; Barlow E; Beckmann MW; Berger J; Bisinotto C; Bösmüller H; Boros J; Brand AH; Brooks-Wilson A; Brucker SY; Carney ME; Casablanca Y; Cazorla-Jiménez A; Cohen PA; Conrads TP; Cook LS; Coulson P; Courtney-Brooks M; Cramer DW; Crowe P; Cunningham JM; Cybulski C; Darcy KM; El-Bahrawy MA; Elishaev E; Erber R; Farrell R; Fereday S; Fischer A; García MJ; Gayther SA; Gentry-Maharaj A; Gilks CB; ; Grube M; Harnett PR; Harrington SP; Harter P; Hartmann A; Hecht JL; Heikaus S; Hein A; Heitz F; Hendley J; Hernandez BY; Polo SH; Heublein S; Hirasawa A; Høgdall E; Høgdall CK; Horlings HM; Huntsman DG; Huzarski T; Jewell A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Khabele D; Kommoss FKF; Kruitwagen RFPM; Lambrechts D; Le ND; Lener M; Lester J; Leung Y; Linder A; Loverix L; Lubiński J; Madan R; Maxwell GL; Modugno F; Neuhausen SL; Olawaiye A; Olbrecht S; Orsulic S; Palacios J; Pearce CL; Pike MC; Quinn CM; Mohan GR; Rodríguez-Antona C; Ruebner M; Ryan A; Salfinger SG; Sasamoto N; Schildkraut JM; Schoemaker MJ; Shah M; Sharma R; Shvetsov YB; Singh N; Sonke GS; Steele L; Stewart CJR; Sundfeldt K; Swerdlow AJ; Talhouk A; Tan A; Taylor SE; Terry KL; Tołoczko A; Traficante N; Van de Vijver KK; van der Aa MA; Van Gorp T; Van Nieuwenhuysen E; van-Wagensveld L; Vergote I; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Wu AH; Benitez J; Berchuck A; Candido Dos Reis FJ; DeFazio A; Fasching PA; Goode EL; Goodman MT; Gronwald J; Karlan BY; Kommoss S; Menon U; Sinn HP; Staebler A; Brenton JD; Bowtell DD; Pharoah PDP; Ramus SJ; Köbel M
Cancer; 2023 Mar; 129(5):697-713. PubMed ID: 36572991
[TBL] [Abstract][Full Text] [Related]
3. HER2 in uterine serous carcinoma: Current state and clinical perspectives.
Navarro Sanchez JM; Finkelman BS; Turner BM; Katerji H; Wang X; Varghese S; Wang T; Peng Y; Hicks DG; Zhang H
Am J Clin Pathol; 2023 Oct; 160(4):341-351. PubMed ID: 37267036
[TBL] [Abstract][Full Text] [Related]
4. Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.
Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
Clin Cancer Res; 2024 Jun; 30(11):2461-2474. PubMed ID: 38536067
[TBL] [Abstract][Full Text] [Related]
5.
Xu H; George E; Kinose Y; Kim H; Shah JB; Peake JD; Ferman B; Medvedev S; Murtha T; Barger CJ; Devins KM; D'Andrea K; Wubbenhorst B; Schwartz LE; Hwang WT; Mills GB; Nathanson KL; Karpf AR; Drapkin R; Brown EJ; Simpkins F
Cell Rep Med; 2021 Sep; 2(9):100394. PubMed ID: 34622231
[No Abstract] [Full Text] [Related]
6. Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.
Ross DS; Devereaux KA; Jin C; Lin DY; Zhang Y; Marra A; Makker V; Weigelt B; Ellenson LH; Chui MH
Mod Pathol; 2022 Jul; 35(7):962-971. PubMed ID: 34972830
[TBL] [Abstract][Full Text] [Related]
7. Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.
Rustgi N; Wu S; Samec T; Walker P; Xiu J; Lou E; Goel S; Saeed A; Moy RH
Cancer Res Commun; 2024 Jun; 4(6):1399-1409. PubMed ID: 38717153
[TBL] [Abstract][Full Text] [Related]
8. Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
[TBL] [Abstract][Full Text] [Related]
9. GCN-5/PGC-1α signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer.
Guo T; Li B; Gu C; Chen X; Han M; Liu X; Xu C
Aging (Albany NY); 2019 Jul; 11(14):4890-4899. PubMed ID: 31313989
[TBL] [Abstract][Full Text] [Related]
10. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
Urick ME; Bell DW
Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
[TBL] [Abstract][Full Text] [Related]
11. WEE1i-ATRi combination therapy: a promising low-dose treatment for
Goehring L; Huang TT
Cell Rep Med; 2021 Sep; 2(9):100402. PubMed ID: 34622238
[No Abstract] [Full Text] [Related]
12. Functional characterization of the 19q12 amplicon in grade III breast cancers.
Natrajan R; Mackay A; Wilkerson PM; Lambros MB; Wetterskog D; Arnedos M; Shiu KK; Geyer FC; Langerød A; Kreike B; Reyal F; Horlings HM; van de Vijver MJ; Palacios J; Weigelt B; Reis-Filho JS
Breast Cancer Res; 2012 Mar; 14(2):R53. PubMed ID: 22433433
[TBL] [Abstract][Full Text] [Related]
13. Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer.
Bai S; Taylor SE; Jamalruddin MA; McGonigal S; Grimley E; Yang D; Bernstein KA; Buckanovich RJ
Mol Cancer Ther; 2022 Sep; 21(9):1473-1484. PubMed ID: 35732503
[TBL] [Abstract][Full Text] [Related]
14. MYC amplifications are common events in childhood osteosarcoma.
De Noon S; Ijaz J; Coorens TH; Amary F; Ye H; Strobl A; Lyskjaer I; Flanagan AM; Behjati S
J Pathol Clin Res; 2021 Sep; 7(5):425-431. PubMed ID: 33969640
[TBL] [Abstract][Full Text] [Related]
15. Copy number variations and protein expression of Cyclin E1 and Epithelial cell transforming sequence 2 genes predict the chemotherapeutic response in patients with serous ovarian carcinoma.
Sarfraz R; Masood A; Zaki S; Shami A; Khaliq S; Naseem N
Pak J Med Sci; 2023; 39(3):835-842. PubMed ID: 37250533
[TBL] [Abstract][Full Text] [Related]
16. Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets.
Lu J; Ding Y; Chen Y; Jiang J; Chen Y; Huang Y; Wu M; Li C; Kong M; Zhao W; Wang H; Zhang J; Li Z; Lu Y; Yu X; Jin K; Zhou D; Zhou T; Teng F; Zhang H; Zhou Z; Wang H; Teng L
Nat Commun; 2021 Jun; 12(1):3946. PubMed ID: 34168152
[TBL] [Abstract][Full Text] [Related]
17. Copy number signatures and CCNE1 amplification reveal the involvement of replication stress in high-grade endometrial tumors oncogenesis.
Marlin R; Loger JS; Joachim C; Ebring C; Robert-Siegwald G; Pennont S; Rose M; Raguette K; Suez-Panama V; Ulric-Gervaise S; Lusbec S; Bera O; Vallard A; Aline-Fardin A; Colomba E; Jean-Laurent M
Cell Oncol (Dordr); 2024 Apr; ():. PubMed ID: 38564163
[TBL] [Abstract][Full Text] [Related]
18. The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations.
Menghi F; Barthel FP; Yadav V; Tang M; Ji B; Tang Z; Carter GW; Ruan Y; Scully R; Verhaak RGW; Jonkers J; Liu ET
Cancer Cell; 2018 Aug; 34(2):197-210.e5. PubMed ID: 30017478
[TBL] [Abstract][Full Text] [Related]
19. Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal.
Talbot T; Lu H; Aboagye EO
Cancer Gene Ther; 2023 Jul; 30(7):955-963. PubMed ID: 36804485
[TBL] [Abstract][Full Text] [Related]
20. Targeting
Xu H; George E; Gallo D; Medvedev S; Wang X; Kryczka R; Hyer ML; Fourtounis J; Stocco R; Aguado-Fraile E; Petrone A; Yin SY; Shiwram A; Anderson M; Kim H; Liu F; Marshall CG; Simpkins F
Res Sq; 2024 Feb; ():. PubMed ID: 38410486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]